Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell W. Jenkins, Rohit Thummalapalli, Jacob Carter, et al.
Annual Review of Medicine (2017) Vol. 69, Iss. 1, pp. 333-347
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini, Fréderic Bibeau, M. Ligtenberg, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1232-1243
Open Access | Times Cited: 828
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, et al.
Nature Cancer (2020) Vol. 1, Iss. 9, pp. 873-881
Closed Access | Times Cited: 362
Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets
Quanyin Hu, Hongjun Li, Edikan Archibong, et al.
Nature Biomedical Engineering (2021) Vol. 5, Iss. 9, pp. 1038-1047
Open Access | Times Cited: 273
Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Li Liu, Xue Bai, Jian Wang, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 24, pp. 7413-7423
Open Access | Times Cited: 267
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 6-23
Closed Access | Times Cited: 177
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, et al.
Journal of Thoracic Oncology (2020) Vol. 15, Iss. 6, pp. 914-947
Open Access | Times Cited: 140
Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy
Yu-Chen Wang, Xi Wang, Jiaji Yu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 115
Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, et al.
PLoS Computational Biology (2019) Vol. 15, Iss. 3, pp. e1006658-e1006658
Open Access | Times Cited: 119
Immunotherapies and Combination Strategies for Immuno-Oncology
Cody Barbari, Tyler Fontaine, Priyanka Parajuli, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5009-5009
Open Access | Times Cited: 103
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
Hongcheng Yang, Ruoyang Shao, Hongxin Huang, et al.
Cancer Medicine (2019) Vol. 8, Iss. 9, pp. 4245-4253
Open Access | Times Cited: 79
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Alexander T. Bauer, Christian Gorzelanny, Christoffer Gebhardt, et al.
Cancer Treatment Reviews (2021) Vol. 102, pp. 102322-102322
Open Access | Times Cited: 61
Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer
Florian Janke, M. Gasser, Arlou Kristina Angeles, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Tumor mutational burden in colorectal cancer: Implications for treatment
A. M. Marques, Patrícia Cavaco, Carla Torre, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104342-104342
Open Access | Times Cited: 7
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Dawei Wu, Shuopeng Jia, Shujun Xing, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Claire Lhuillier, Claire Vanpouille‐Box, Lorenzo Galluzzi, et al.
Seminars in Cancer Biology (2017) Vol. 52, pp. 125-134
Open Access | Times Cited: 54
Tumor-Derived cGAMP Regulates Activation of the Vasculature
Marco Campisi, Shriram K. Sundararaman, Sarah E. Shelton, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 48
Comparison between tumors in plants and human beings: Mechanisms of tumor development and therapy with secondary plant metabolites
C. Ullrich, Roni Aloni, Mohamed E.M. Saeed, et al.
Phytomedicine (2019) Vol. 64, pp. 153081-153081
Closed Access | Times Cited: 44
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Ronnie Shapira-Frommer, Jiaxin Niu, Ruth Perets, et al.
Future Oncology (2024) Vol. 20, Iss. 27, pp. 1983-1991
Open Access | Times Cited: 5
Two heteropolysaccharides from Isaria cicadae Miquel differ in composition and potentially immunomodulatory activity
Zhanchi Xu, Xiaoteng Yan, Zhuoyue Song, et al.
International Journal of Biological Macromolecules (2018) Vol. 117, pp. 610-616
Closed Access | Times Cited: 41
Coagulation and inflammation in cancer: Limitations and prospects for treatment
Arun Kumar Singh, Rishabha Malviya
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 3, pp. 188727-188727
Closed Access | Times Cited: 22
MerTK + macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation
Naming Wu, Jun Li, Lu Li, et al.
Science Advances (2024) Vol. 10, Iss. 40
Open Access | Times Cited: 4
Neuritin-specific antibody impedes the Treg-mediated suppression of anti-tumor immunity and enhances response to anti-PD1
Kaimin Zhang, Tingcun Zhao, Faisal Riaz, et al.
Molecular Immunology (2025) Vol. 181, pp. 148-159
Open Access
The DNA damage response in immunotherapy and radiation
Robert M. Samstein, Nadeem Riaz
Advances in Radiation Oncology (2018) Vol. 3, Iss. 4, pp. 527-533
Open Access | Times Cited: 25
The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors
Omar Alkharabsheh, M Hasib Sidiqi, Mohammed A. Aljama, et al.
Acta Haematologica (2019) Vol. 143, Iss. 2, pp. 118-123
Open Access | Times Cited: 23
Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy
Stephen K. Doberstein
Expert Opinion on Biological Therapy (2019) Vol. 19, Iss. 12, pp. 1223-1228
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top